Mizuho on Cartesian Therapeutics (RNAC): 'We believe the potential of Descartes-08 remains underappreciated'
Tweet Send to a Friend
Mizuho analyst Uy Ear reiterated an Outperform rating and $40.00 price target on Cartesian Therapeutics (NASDAQ: RNAC).The analyst comments "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
